Publications in collaboration with researchers from Universidad de Salamanca (86)

2024

  1. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  2. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  3. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

    Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651

  4. Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke

    iScience, Vol. 27, Núm. 11

  5. Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury

    Spinal Cord, Vol. 62, Núm. 8, pp. 454-467

  6. Rare Genetic Variants in Young Adults Requiring Pacemaker Implantation

    JACC: Clinical Electrophysiology, Vol. 10, Núm. 10, pp. 2250-2260

  7. Relationship between Mental Disorders, Smoking or Alcoholism and Benign Prostate Disease

    CLINICS AND PRACTICE, Vol. 14, Núm. 1, pp. 250-264

  8. Stratification of Colorectal Patients Based on Survival Analysis Shows the Value of Consensus Molecular Subtypes and Reveals the CBLL1 Gene as a Biomarker of CMS2 Tumours

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  3. El estilo de pensamiento ¿un determinante frente al síndrome de Burnout?

    Enfermería Nefrológica, Vol. 26, Núm. Supl. 1, pp. 31

  4. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

    Frontiers in immunology, Vol. 14, pp. 1310211

  5. Expert opinion paper on the treatment of hemophilia a with emicizumab

    Hematology (Amsterdam, Netherlands), Vol. 28, Núm. 1, pp. 2166334

  6. Exploring High-Throughput Immunoassays for Biomarker Validation in Rheumatic Diseases in the Context of the Human Proteome Project

    Journal of Proteome Research, Vol. 22, Núm. 4, pp. 1105-1115

  7. Impact of days elapsed from the onset of symptoms to hospitalization in COVID-19 in-hospital mortality: Time matters

    Revista Clinica Espanola, Vol. 223, Núm. 5, pp. 281-297

  8. Nosocomial COVID-19: A Nationwide Spanish Study

    Gerontology, Vol. 69, Núm. 6, pp. 671-683

  9. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 5, pp. 382-396

  10. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project

    Orphanet Journal of Rare Diseases, Vol. 18, Núm. 1

  11. Relación entre sobrehidratación y marcadores biológicos CA 125 y NT-PRO-BNP en pacientes en hemodiálisis como predictores de insuficiencia cardiaca

    Enfermería Nefrológica, Vol. 26, Núm. Supl. 1, pp. 72

  12. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490